Focused on immunology-based therapies for infectious diseases, this biotech company reported a notable insider sale in recent ...

Flying on a plane out of Boston, Paul Belcher broke the habit of a lifetime. I’m an introvert; I do not like people talking to me on aeroplanes,” he says. But the man sitting next to him started ...

Vir Biotechnology has a cash runway into 2028 and pivotal 2026 catalysts for its lead hepatitis drugs. Learn why VIR stock is ...

Our country did not cede the nuclear race to the Soviet Union, and we cannot cede the biotechnology race to China now.

Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual ...

From the early days of the Manhattan Project to the race to develop artificial intelligence, America has long recognized that being at the forefront of emerging technologies is critical to our ...

Discover the role of biotechnology in healthcare, medicine, and investment. Understand biotech processes, top companies, and ...

Biotechnology stocks are among the most high-risk, high-reward stocks in the market. Many biotech companies are working to ...

Biotechnology is a curious marriage of two seemingly disparate worlds. On one end, we have living organisms—wild, unpredictable celestial creations that can probably never be understood or appreciated ...

PDS Biotechnology (NASDAQ:PDSB) reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck ...

Is VIR a good stock to buy? We came across a bullish thesis on Vir Biotechnology, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on VIR. Vir Biotechnology, ...

Sana Biotechnology (SANA) is back in focus after Mayo Clinic agreed to collaborate on SC451 for type 1 diabetes and invest up to US$50 million, linking clinical expertise with fresh capital support.